{"id":"direct-acting-antivirals","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAAs work by directly targeting and blocking specific viral proteins such as proteases, polymerases, or other essential enzymes needed for the viral life cycle. This class is most well-established for hepatitis C virus (HCV) treatment, where combinations of DAAs targeting different viral proteins have achieved cure rates exceeding 95%. The mechanism differs from older interferon-based therapies by directly interfering with viral replication machinery rather than boosting immune response.","oneSentence":"Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from multiplying within host cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:23.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatitis C virus (HCV) infection"},{"name":"Potentially other viral infections depending on specific agent"}]},"trialDetails":[{"nctId":"NCT03520660","phase":"PHASE4","title":"People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2018-10-19","conditions":"Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases","enrollment":121},{"nctId":"NCT07169318","phase":"PHASE1","title":"First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-16","conditions":"Influenza","enrollment":78},{"nctId":"NCT04979728","phase":"","title":"HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-05-27","conditions":"HIV Treatment, HIV Prevention","enrollment":150},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT03383419","phase":"PHASE2","title":"Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2018-03-20","conditions":"Heart Failure","enrollment":15},{"nctId":"NCT07097870","phase":"","title":"Predictors of HCC in Post-HCV Cirrhotic Patients After SVR","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-08","conditions":"HCC - Hepatocellular Carcinoma","enrollment":400},{"nctId":"NCT06952036","phase":"","title":"The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-04-25","conditions":"HCV Infection, HCV Elimination","enrollment":200000},{"nctId":"NCT05637879","phase":"PHASE2, PHASE3","title":"Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder","status":"RECRUITING","sponsor":"White River Junction Veterans Affairs Medical Center","startDate":"2023-12-18","conditions":"PTSD","enrollment":92},{"nctId":"NCT06928259","phase":"","title":"Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV","status":"RECRUITING","sponsor":"University of Seville","startDate":"2025-04-30","conditions":"HCV Infection","enrollment":728},{"nctId":"NCT04698629","phase":"","title":"Hepatitis C Pharmacy-based Strategy for Injectors","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-05","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT03902366","phase":"","title":"HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-05-16","conditions":"Hepatitis C, Alcohol Use Disorder","enrollment":63},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02578693","phase":"","title":"Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":1210},{"nctId":"NCT03221309","phase":"","title":"Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"HCV, Buprenorphine, PreP","enrollment":198},{"nctId":"NCT04885855","phase":"PHASE2, PHASE3","title":"8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Muhammad Radzi Abu Hassan","startDate":"2021-03-23","conditions":"Hepatitis C","enrollment":322},{"nctId":"NCT06872047","phase":"","title":"Exploring the Knowledge, Attitudes, Behaviors and Perceived Barriers of Hepatologists Towards Non-invasive Hepatocellular Carcinoma Prediction Models in Hepatitis C Patients Who Achieved Sustained Virological Response Following Direct Acting Antivirals Therapy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-04-01","conditions":"Non-invasive Hepatocellular Carcinoma","enrollment":400},{"nctId":"NCT06834178","phase":"","title":"Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria","status":"NOT_YET_RECRUITING","sponsor":"Vanessa Stadlbauer-Koellner, MD","startDate":"2025-04","conditions":"HBV, HCV, HDV","enrollment":100},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT02824315","phase":"PHASE1","title":"Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05","conditions":"Healthy","enrollment":22},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT05368974","phase":"","title":"The Treatment in Pregnancy for Hepatitis C (\"TiP-HepC\") Registry","status":"RECRUITING","sponsor":"The Task Force for Global Health","startDate":"2022-02-11","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT04515797","phase":"PHASE4","title":"QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2021-05-01","conditions":"Kidney Failure, Hepatitis C, Kidney Disease, Chronic","enrollment":2},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT02824640","phase":"NA","title":"Patient-Centered Models of HCV Care for People Who Inject Drugs","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2016-09-15","conditions":"Hepatitis C, Medication Adherence","enrollment":755},{"nctId":"NCT04042740","phase":"PHASE2","title":"Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-11-20","conditions":"Hepatitis C Infection, HIV Infection","enrollment":45},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT06325826","phase":"","title":"The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Egyptian Liver Hospital","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":500},{"nctId":"NCT05506475","phase":"","title":"Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Institut Pasteur","startDate":"2024-05","conditions":"HIV Infection, Hepatitis C Infection","enrollment":400},{"nctId":"NCT03685045","phase":"NA","title":"ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2018-05-28","conditions":"Hepatitis C","enrollment":6000},{"nctId":"NCT04513899","phase":"NA","title":"Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2020-10-05","conditions":"Hepatitis C Virus (HCV) Infection","enrollment":10},{"nctId":"NCT04330508","phase":"","title":"Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-03-01","conditions":"Depression in Chronic Hepatitis C","enrollment":385},{"nctId":"NCT03566966","phase":"","title":"Autoantibodies and Direct-acting Antivirals","status":"COMPLETED","sponsor":"University of Bari","startDate":"2015-07-01","conditions":"Viral Hepatitis C, Therapy Adverse Effect","enrollment":191},{"nctId":"NCT05466331","phase":"NA","title":"Rural New England Health Study (Phase 2)","status":"UNKNOWN","sponsor":"Baystate Medical Center","startDate":"2022-05-18","conditions":"Hepatitis C, Opioid Use Disorder, IV Drug Usage","enrollment":220},{"nctId":"NCT03248622","phase":"","title":"Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-06-03","conditions":"Hepatitis B","enrollment":79},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT03801707","phase":"PHASE2, PHASE3","title":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-03-22","conditions":"Kidney Transplant, Hepatitis C, HCV","enrollment":54},{"nctId":"NCT04159545","phase":"","title":"Future Destinations: Journeys Towards Citizenship","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-12-15","conditions":"Hepatitis C, Drug Use","enrollment":15},{"nctId":"NCT05542615","phase":"PHASE2","title":"Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2019-08-01","conditions":"Liver Cirrhosis, Hepatitis C, Chronic, Epigenetic Disorder","enrollment":60},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT03702218","phase":"EARLY_PHASE1","title":"Hepatitis C Positive Donor Into Hepatitis C Negative Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT05460130","phase":"NA","title":"Implementing HCV Treatment for High-risk Populations in Austin, Texas","status":"UNKNOWN","sponsor":"University of Texas at Austin","startDate":"2022-09-29","conditions":"Hepatitis C Virus Infection","enrollment":64},{"nctId":"NCT04653818","phase":"PHASE4","title":"HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-10-05","conditions":"Hepatocellular Carcinoma, Hepatitis C, Neoplasm Recurrence","enrollment":84},{"nctId":"NCT04353986","phase":"PHASE3","title":"PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-06-11","conditions":"HCV Infection, Beta Thalassemia Major","enrollment":24},{"nctId":"NCT02510300","phase":"","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-10-21","conditions":"Hepatitis C Virus Infection","enrollment":461},{"nctId":"NCT03086044","phase":"PHASE4","title":"Transplanting Hepatitis C Positive Organs","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2017-03-01","conditions":"Hepatitis C, Awaiting Organ Transplant","enrollment":148},{"nctId":"NCT04320290","phase":"PHASE4","title":"HCV + to HCV - Kidney Transplant","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-21","conditions":"Kidney Failure, Hepatitis C","enrollment":""},{"nctId":"NCT03208127","phase":"PHASE4","title":"DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-21","conditions":"End Stage Liver Disease, Hepatitis C","enrollment":33},{"nctId":"NCT04008927","phase":"NA","title":"A Community-based Intervention Among Active Drug Users in Montpellier","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-18","conditions":"Drug Use, HCV Infection","enrollment":554},{"nctId":"NCT05452187","phase":"","title":"Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study","status":"COMPLETED","sponsor":"Hospital Mutua de Terrassa","startDate":"2021-03-12","conditions":"Inflammatory Bowel Diseases, Hepatitis C Virus Infection","enrollment":79},{"nctId":"NCT05170490","phase":"","title":"Long Term Follow up of Chronic HCV Patients Receiving DAAS","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2018-06-01","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT03208244","phase":"PHASE4","title":"DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-09","conditions":"End Stage Heart Disease, Hepatitis C","enrollment":40},{"nctId":"NCT05376943","phase":"","title":"Possible Differences in HCC Course Depending on DAA Treatment","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2022-05-10","conditions":"Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of, Drug Effect","enrollment":100},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT04719338","phase":"NA","title":"Occult HCV Infection After DAAD Treatment in Haemodialysis Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-03-01","conditions":"Hepatitis C","enrollment":30},{"nctId":"NCT03343925","phase":"","title":"Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2018-08-17","conditions":"Hepatitis C, Chronic","enrollment":140},{"nctId":"NCT03740906","phase":"","title":"Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-09-06","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT03200379","phase":"","title":"Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan","status":"RECRUITING","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2017-06-15","conditions":"Hepatitis C, Chronic","enrollment":150000},{"nctId":"NCT05284916","phase":"","title":"Difference in Patterns of Liver Diseases Related Admissions After the Era of DAAS","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-03-15","conditions":"Patternsof Liver Diseasesadmissions After Era of DAAS","enrollment":200},{"nctId":"NCT02938013","phase":"PHASE4","title":"deLIVER: Direct Acting Antiviral Effects on the Liver","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"HCV Coinfection, Liver Disease, HIV","enrollment":15},{"nctId":"NCT02581020","phase":"","title":"The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-14","conditions":"Hepatitis C Virus","enrollment":344},{"nctId":"NCT05062408","phase":"","title":"Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2021-03-01","conditions":"Hepatitis C, Chronic","enrollment":321},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT03935906","phase":"NA","title":"Reaching mEthadone Users Attending Community pHarmacies With HCV","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT03127358","phase":"NA","title":"Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2017-11-14","conditions":"Hepatitis C, Medication Adherence","enrollment":11},{"nctId":"NCT02102451","phase":"","title":"Control and Elimination Within Australia of Hepatitis C From People Living With HIV","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2014-07","conditions":"Hepatitis C, HIV, HIV-HCV Coinfection","enrollment":492},{"nctId":"NCT03551002","phase":"","title":"Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego","status":"UNKNOWN","sponsor":"University of California, San Diego","startDate":"2018-01-01","conditions":"Hepatitis C, Hepatitis C, Chronic, HIV/AIDS","enrollment":450},{"nctId":"NCT04251572","phase":"NA","title":"HCV Reinfection After DAA Therapy in PWID in Belgium","status":"UNKNOWN","sponsor":"Hasselt University","startDate":"2019-07-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of, Drug Use","enrollment":100},{"nctId":"NCT04039698","phase":"NA","title":"Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-08-23","conditions":"Chronic Hepatitis C","enrollment":144},{"nctId":"NCT02247401","phase":"PHASE3","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-04","conditions":"HCV, Hepatitis C Infection, Genotype 4","enrollment":160},{"nctId":"NCT03200171","phase":"","title":"Effect of DAAs on Behavior of HCC in HCV Patients","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2018-02-10","conditions":"Carcinoma, Hepatocellular, Hepatitis C","enrollment":300},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03707080","phase":"","title":"Direct Acting Antiviral-Post Authorization Safety Study","status":"COMPLETED","sponsor":"Target PharmaSolutions, Inc.","startDate":"2018-03-09","conditions":"Hepatitis C, Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT02969668","phase":"","title":"Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Opioid-Related Disorders","enrollment":326},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT01532908","phase":"PHASE2","title":"Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C","status":"TERMINATED","sponsor":"MassBiologics","startDate":"2012-11-21","conditions":"Hepatitis C Infection","enrollment":11},{"nctId":"NCT03939013","phase":"NA","title":"Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)","status":"COMPLETED","sponsor":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","startDate":"2019-01-30","conditions":"Hepatitis C","enrollment":634},{"nctId":"NCT02533934","phase":"PHASE4","title":"Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"HIV, Hepatitis C, Cirrhosis","enrollment":68},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT04662138","phase":"","title":"Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-08-24","conditions":"Hepatitis C, Relapse, Antivirals","enrollment":100},{"nctId":"NCT02505243","phase":"","title":"Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-06","conditions":"HCV Coinfection, Hepatitis C","enrollment":252},{"nctId":"NCT04201808","phase":"PHASE4","title":"Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides","status":"UNKNOWN","sponsor":"New Discovery LLC","startDate":"2021-05-01","conditions":"Hepatitis B, Chronic","enrollment":100},{"nctId":"NCT02526641","phase":"","title":"Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-08","conditions":"Hepatitis C","enrollment":16},{"nctId":"NCT03820258","phase":"PHASE2","title":"Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-01-28","conditions":"Hepatitis C Virus Infection","enrollment":21},{"nctId":"NCT03444272","phase":"PHASE3","title":"Effect of Direct-acting Antiviral Drugs on Erectile Function","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-01-01","conditions":"Hepatitis C","enrollment":105},{"nctId":"NCT02441283","phase":"PHASE2, PHASE3","title":"A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06-22","conditions":"Hepatitis C","enrollment":384},{"nctId":"NCT02185794","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-06-13","conditions":"Hepatitis C Virus Infection","enrollment":101},{"nctId":"NCT04460157","phase":"","title":"Prediction of Liver-related Outcomes After HCV Cure","status":"UNKNOWN","sponsor":"Hospital Universitario de Valme","startDate":"2011-10","conditions":"Hepatitis C, Chronic, Sustained Virological Response, Direct-acting Antivirals","enrollment":1035},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT02118012","phase":"PHASE1, PHASE2","title":"Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-03-20","conditions":"Chronic Hepatitis C","enrollment":24},{"nctId":"NCT03381859","phase":"PHASE4","title":"Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-12-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of","enrollment":""},{"nctId":"NCT01945008","phase":"","title":"Observational Study in HCV Chronic Infection","status":"COMPLETED","sponsor":"Istituto Superiore di Sanità","startDate":"2014-04","conditions":"Hepatitis C, Chronic","enrollment":7600}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"HEPATOCELLULAR CARCINOMA"},{"count":1,"reaction":"AGITATION"},{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"APHASIA"},{"count":1,"reaction":"BLISTER"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DERMATITIS ALLERGIC"},{"count":1,"reaction":"DISORIENTATION"},{"count":1,"reaction":"EPILEPSY"}],"_approvalHistory":[],"publicationCount":5079,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DAAs in Non Cirrhotics","Sofosbuvir","Daclatasvir","Ledipasvir","Direct Acting Antiviral HCV Treatment"],"phase":"marketed","status":"active","brandName":"Direct Acting Antivirals","genericName":"Direct Acting Antivirals","companyName":"Medical University of Warsaw","companyId":"medical-university-of-warsaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from multiplying within host cells. Used for Hepatitis C virus (HCV) infection, Potentially other viral infections depending on specific agent.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}